ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.163,52
-0,41%
S&P 500
5.464,62
-0,16%
Dow Jones
39.150,33
0,04%
Euro vs US Dollar
1,06925
0,00%
Bitcoin
64.066,08
-0,28%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Mangoceuticals Inc (MGRX)

  7. Mangoceuticals Inc (MGRX) News

MGRX

Mangoceuticals (MGRX)

Mangoceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:MGRX
DatumZeitQuelleÜberschriftSymbolFirma
18/06/202420h57Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MGRXMangoceuticals Inc
10/06/202419h28Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MGRXMangoceuticals Inc
06/06/202414h30GlobeNewswire Inc.MangoRx Receives Notice of Acceptance for Patent Application in Australia for Respiratory Illness and Preventive Care TechnologyNASDAQ:MGRXMangoceuticals Inc
05/06/202423h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MGRXMangoceuticals Inc
05/06/202423h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MGRXMangoceuticals Inc
05/06/202423h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MGRXMangoceuticals Inc
04/06/202422h00GlobeNewswire Inc.MangoRx Receives Patent Notice of Allowance in Japan for Revolutionary Preventive Care Technology Acquired from Intramont TechnologiesNASDAQ:MGRXMangoceuticals Inc
04/06/202414h00GlobeNewswire Inc.MangoRx to Introduce “MOJO” Pharmaceutical Compounded Formula Featuring Enclomiphene Citrate and Pregnenolone for Treatment of Low Testosterone and Male Hormone ImbalancesNASDAQ:MGRXMangoceuticals Inc
28/05/202414h30GlobeNewswire Inc.Mangoceuticals, Inc. Announces Completion of First Batch of Mango ED Products for Marketing and Distribution in Mexico and Latin American MarketsNASDAQ:MGRXMangoceuticals Inc
23/05/202414h30GlobeNewswire Inc.MangoRx Engages Renown International Digital and Performance Marketing Company Crakmedia to Champion its Digital Marketing EffortsNASDAQ:MGRXMangoceuticals Inc
21/05/202414h30GlobeNewswire Inc.MangoRx to Introduce Oral Semaglutide and Tirzepatide in Response to Increasing Patient Demand for GLP-1 MedicationsNASDAQ:MGRXMangoceuticals Inc
16/05/202422h40GlobeNewswire Inc.MangoRx Reports Revenue Growth of 108% in Q1 2024 Fueled by Amplified Customer Acquisition and Early Market PenetrationNASDAQ:MGRXMangoceuticals Inc
16/05/202419h59Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:MGRXMangoceuticals Inc
16/05/202415h19Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:MGRXMangoceuticals Inc
15/05/202422h52Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MGRXMangoceuticals Inc
14/05/202415h00Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:MGRXMangoceuticals Inc
10/05/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:MGRXMangoceuticals Inc
06/05/202423h32Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:MGRXMangoceuticals Inc
06/05/202422h43Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:MGRXMangoceuticals Inc
02/05/202414h00GlobeNewswire Inc.Mangoceuticals Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement and Conditional Approval of Compliance with Nasdaq’s Minimum Stockholders’ Equity RequirementNASDAQ:MGRXMangoceuticals Inc
25/04/202414h30GlobeNewswire Inc.Mangoceuticals Acquires Global Patent Portfolio to Revolutionize Preventive CareNASDAQ:MGRXMangoceuticals Inc
12/04/202414h45GlobeNewswire Inc.Mangoceuticals Subsidiary, MangoRx Mexico, Executes Technical Agreement with Mexican Pharmaceutical Manufacturer for Initial Development and Production of its Mango Erectile Dysfunction (ED) ProductsNASDAQ:MGRXMangoceuticals Inc
12/03/202414h00GlobeNewswire Inc.MangoRx Officially Launches ‘PRIME’ by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) TreatmentNASDAQ:MGRXMangoceuticals Inc
20/02/202415h00GlobeNewswire Inc.MangoRx Launches Direct-To-Clinics Sales Division to Drive and Fuel Customer Acquisition and Revenue GrowthNASDAQ:MGRXMangoceuticals Inc
13/02/202414h00GlobeNewswire Inc.MANGORX AWARDS SAN FRANCISCO TEAM FREE MANGORX ED PRODUCTS FOR ONE YEAR FOLLOWING BIG GAME LOSS TO KANSAS CITYNASDAQ:MGRXMangoceuticals Inc
06/02/202415h00GlobeNewswire Inc.MANGORX TO OFFER THE BIG GAME’S LOSING TEAM A FREE ONE YEAR SUPPLY OF ITS ED PRODUCT, MANGO, TO HELP RAISE… SPIRITSNASDAQ:MGRXMangoceuticals Inc
05/02/202414h50GlobeNewswire Inc.MangoRx Accepting Pre Orders for its “PRIME”, by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) ProductNASDAQ:MGRXMangoceuticals Inc
19/01/202414h00GlobeNewswire Inc.MangoRx’s Brand and Products to be Featured by Barstool Sports in Week of Programming Around the Biggest Sports Event of the Year on February 11NASDAQ:MGRXMangoceuticals Inc
15/12/202316h39GlobeNewswire Inc.Mangoceuticals, Inc. Announces Pricing of $1,200,000 Public OfferingNASDAQ:MGRXMangoceuticals Inc
13/12/202313h30GlobeNewswire Inc.MANGOCEUTICALS TO INTRODUCE “PRIME”, POWERED BY KYZATREX®️ (CIII TESTOSTERONE UNDECANOATE CAPSULES), FOR AN FDA APPROVED ORAL TESTOSTERONE REPLACEMENT THERAPY (TRT) PRODUCTNASDAQ:MGRXMangoceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:MGRX

Kürzlich von Ihnen besucht

COIN
ABAETH
BIT
F17382
Vontobel Financial Produ...
LSE
47LS
Res.mort.4'm' S
USOTC
CXBTF
XBT Provider AB Bitcoin ... (CE)
COIN
NOOBTC
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten